Rituximab in Treating Patients With Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them. PURPOSE: Phase II trial to study the effectiveness of the monoclonal antibody rituximab in treating patients with multiple myeloma that is newly diagnosed.

Key facts

Study ID

NCT00003554

Run by

The Cleveland Clinic

Starts

1998-11-01

Expected to finish

2004-04-01

Last updated by the study team

2013-07-18

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.